

IFW

PATENT
Attorney Docket No. 061030-0055
(Formerly 10602-055)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: D. SOLOW-CORDERO et al.

Application No.: 10/760,002

Confirmation No.: 8662

Filed: January 16, 2004

Group Art Unit: 1645

For: METHODS OF TREATING CONDITIONS
ASSOCIATED WITH EDG-7 RECEPTOR

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97**

U.S. Patent and Trademark Office
Commissioner For Patents
2011 Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to References C01-C04, cited on the attached Revised PTO Form 1449. A copy of references C01-C04 is also submitted herewith.


Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references therein as "Prior Art." As an alternative, Applicants submit herewith a "revised PTO Form 1449" entitled "List of References Cited By Applicant" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review all of the references and make them of record in the present application by signing and returning the enclosed List of References Cited.

Pursuant to 37 C.F.R. § 1.97(b)(3), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, so that no fee is believed to be due. However, should the Patent Office determine otherwise, please charge the required fee to Morgan, Lewis & Bockius LLP Deposit Account 50-0310.

Dated: July 22, 2004
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Dean L. Fanelli
Registration No. 48,907

Enclosures

LIST OF REFERENCES CITED BY APPLICANT
(Revised PTO Form 1449)



ATTY DOCKET NO.

APPLICATION NO

061030-0055

10/760,002

APPLICANT

D. SOLOW-CORDERO et al.

FILING DATE

GROUP

January 16, 2004

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01						
	A02						
	A03						
	A04						
	A05						
	A06						
	A07						
	A08						
	A09						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	K. Bando et al., "Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species Structure-activity relationship of cloned LPA receptors," <u>Federation of European Biochemical Societies</u> , 478 (2000) 159-165.
C02	D. Im et al., "Molecular Cloning and Characterization of a Lysophosphatidic Acid Receptor, Edg-7, Expressed in Prostate," <u>The American Society for Pharmacology and Experimental Therapeutics</u> , 57:753-759 (2000).
C03	Annals of the New York Academy of Sciences, Vol. 905:1-357, Lysophospholipids and Eicosanoids in Biology and Pathophysiology, Edited by Edward J. Goetzl and Kevin R. Lynch, 2000.
C04	M. Gräler et al., "EDG6, a Novel G-Protein-Coupled Receptor Related to Receptors for Bioactive Lysophospholipids, Is Specifically Expressed in Lymphoid Tissue," <u>Genomics</u> 53, 164-169 (1998), Article No. GE985491.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.